Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: May, 2017 | Pages:
73 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Human Papillomavirus Protein E6 (E6) - Pipeline Review, H1 2017 Summary Human Papillomavirus Protein E6 (E6) - The Human Papillomavirus (HPV) E6 protein is one of oncoproteins encoded by the virus. It is a 151 amino-acid peptide. It plays a major role in the induction and maintenance of cellular transformation. It acts mainly as an oncoprotein by stimulating the destruction of many host cell key regulatory proteins. The complex E6/E6P targets several other substrates to degradation via the proteasome including host NFX1-91. The resulting increased expression of hTERT prevents the shortening of telomere length leading to cell immortalization. Human Papillomavirus Protein E6 (E6) pipeline Target constitutes close to 24 molecules. Out of which approximately 17 molecules are developed by companies and remaining by the universities/institutes. The molecules developed by companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 4, 2, 9 and 1 respectively. Similarly, the universities portfolio in Phase II, Preclinical and Discovery stages comprises 2, 3 and 2 molecules, respectively. Report covers products from therapy areas Oncology, Women's Health and Infectious Disease which include indications Human Papillomavirus (HPV) Associated Cancer, Cervical Cancer, Head And Neck Cancer Squamous Cell Carcinoma, Cervical Intraepithelial Neoplasia (CIN), Head And Neck Cancer, Human Papillomavirus Infections and Lung Cancer. The latest report Human Papillomavirus Protein E6 (E6) - Pipeline Review, H1 2017, outlays comprehensive information on the Human Papillomavirus Protein E6 (E6) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews key players involved in Human Papillomavirus Protein E6 (E6) targeted therapeutics development with respective active and dormant or discontinued projects. The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Scope - The report provides a snapshot of the global therapeutic landscape for Human Papillomavirus Protein E6 (E6) - The report reviews Human Papillomavirus Protein E6 (E6)targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources - The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages - The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in Human Papillomavirus Protein E6 (E6) targeted therapeutics and enlists all their major and minor projects - The report assesses Human Papillomavirus Protein E6 (E6)targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type - The report summarizes all the dormant and discontinued pipeline projects - The report reviews latest news and deals related to Human Papillomavirus Protein E6 (E6) targeted therapeutics Reasons to buy - Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Identify and understand the targeted therapy areas and indications for Human Papillomavirus Protein E6 (E6) - Identify the use of drugs for target identification and drug repurposing - Identify potential new clients or partners in the target demographic - Develop strategic initiatives by understanding the focus areas of leading companies - Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics - Devise corrective measures for pipeline projects by understanding Human Papillomavirus Protein E6 (E6)development landscape - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope
Table of Contents
List of Tables List of Figures Introduction Global Markets Direct Report Coverage Human Papillomavirus Protein E6 (E6) - Overview Human Papillomavirus Protein E6 (E6) - Therapeutics Development Products under Development by Stage of Development Products under Development by Therapy Area Products under Development by Indication Products under Development by Companies Products under Development by Universities/Institutes Human Papillomavirus Protein E6 (E6) - Therapeutics Assessment Assessment by Mechanism of Action Assessment by Route of Administration Assessment by Molecule Type Human Papillomavirus Protein E6 (E6) - Companies Involved in Therapeutics Development Abion Inc BioNTech AG Cancer Research Technology Ltd Etubics Corp Genexine Inc Hookipa Biotech AG Inovio Pharmaceuticals Inc MedImmune LLC Rottapharm Biotech Srl Selecta Biosciences Inc Tomegavax Inc Transgene SA Human Papillomavirus Protein E6 (E6) - Drug Profiles ABN-301 - Drug Profile Product Description Mechanism Of Action R&D Progress Antibodies to Inhibit E6 for HPV Associated Cancer - Drug Profile Product Description Mechanism Of Action R&D Progress ETBX-041 - Drug Profile Product Description Mechanism Of Action R&D Progress Gene Therapy for Human Papilloma Virus Associated Cervical Intraepithelial Neoplasia - Drug Profile Product Description Mechanism Of Action R&D Progress Gene Therapy to Inhibit E6 and E7 for HPV Associated Cervical Cancer - Drug Profile Product Description Mechanism Of Action R&D Progress GX-188E - Drug Profile Product Description Mechanism Of Action R&D Progress HB-201 - Drug Profile Product Description Mechanism Of Action R&D Progress human papillomavirus [serotype 16] vaccine 1 - Drug Profile Product Description Mechanism Of Action R&D Progress human papillomavirus [serotypes 16] vaccine - Drug Profile Product Description Mechanism Of Action R&D Progress human papillomavirus vaccine - Drug Profile Product Description Mechanism Of Action R&D Progress INO-3106 - Drug Profile Product Description Mechanism Of Action R&D Progress MEDI-0457 - Drug Profile Product Description Mechanism Of Action R&D Progress Monoclonal Antibody to Inhibit E6 for Human Papillomavirus (HPV) Associated Cancer - Drug Profile Product Description Mechanism Of Action R&D Progress PVX-01 - Drug Profile Product Description Mechanism Of Action R&D Progress SEL-701 - Drug Profile Product Description Mechanism Of Action R&D Progress Small Molecules to Inhibit E6 for Human Papillomavirus Associated Cancer - Drug Profile Product Description Mechanism Of Action R&D Progress Subunit Vaccine for HPV Associated Cervical Cancer - Drug Profile Product Description Mechanism Of Action R&D Progress Synthetic Peptide to Inhibit HPV E6 Protein for HPV Associated Cancer - Drug Profile Product Description Mechanism Of Action R&D Progress TA-CIN - Drug Profile Product Description Mechanism Of Action R&D Progress TG-4001 - Drug Profile Product Description Mechanism Of Action R&D Progress Tricurin - Drug Profile Product Description Mechanism Of Action R&D Progress Vaccine to Target HPV E6 for Cervical Intraepithelial Neoplasia - Drug Profile Product Description Mechanism Of Action R&D Progress VGX-3100 - Drug Profile Product Description Mechanism Of Action R&D Progress Vvax-001 - Drug Profile Product Description Mechanism Of Action R&D Progress Human Papillomavirus Protein E6 (E6) - Dormant Products Human Papillomavirus Protein E6 (E6) - Discontinued Products Human Papillomavirus Protein E6 (E6) - Product Development Milestones Featured News & Press Releases May 10, 2017: Inovio Provides Update on MedImmune Launch of Combination Trial for HPV-associated Head & Neck Cancer Apr 24, 2017: Inovio Initiates Phase 2 Efficacy Trial with VGX-3100 For HPV-Related Vulvar Pre-Cancers Mar 06, 2017: Dr Igor Matushansky Appointed Global Head, Research and Development of Hookipa Biotech Nov 14, 2016: Inovios Cancer Immunotherapy (INO-3112) Generates T Cell Immune Responses in Tumor Tissue and Peripheral Blood in Patients with HPV-Associated Head and Neck Cancer Oct 24, 2016: Inovio Announces FDA Request for Additional Information For Phase III Program; Trial Initiation Delayed Oct 17, 2016: Hookipa Secures EUR 4.16 Million Additional Grant Support from the Austrian Research Promotion Agency (FFG) to Develop Arenavirus Vector-Based Cancer Immunotherapies Oct 12, 2016: Inovio Expands Executive Team to Advance its DNA Immunotherapy Product Portfolio Jun 21, 2016: Genexine Presents Interim Clinical Data of GX-188E at EUROGIN 2016 Mar 30, 2016: Inovio Pharmaceuticals HPV Immunotherapy Selected as "Best Therapeutic Vaccine" by World Vaccine Congress Mar 29, 2016: Inovio Updates INO-3112 HPV Immunotherapy Development Plan Nov 05, 2015: Inovio's INO-3112 Shows Robust Immune Responses in Patients With Head & Neck Cancer Sep 17, 2015: Inovio Pharmaceuticals Publishes Successful Phase 2b Trial Results of Its HPV Immunotherapy in The Lancet Jul 23, 2015: Inovio Pharmaceuticals and European Organization for Research and Treatment of Cancer to Collaborate on Large Phase II Cervical Cancer Trial Apr 23, 2015: Global clinical development accelerated as cervical intraepithelial neoplasia therapeutic, GX-188E received expanded approval for Phase II from Europe Apr 09, 2015: Inovio Pharmaceuticals' HPV Immunotherapy Recognized as "Best Therapeutic Vaccine" by World Vaccine Congress Appendix Methodology Coverage Secondary Research Primary Research Expert Panel Validation Contact Us Disclaimer
List of Tables
Number of Products under Development by Stage of Development, H1 2017 Number of Products under Development by Therapy Areas, H1 2017 Number of Products under Development by Indication, H1 2017 Number of Products under Development by Companies, H1 2017 Products under Development by Companies, H1 2017 Products under Development by Companies, H1 2017 (Contd..1), H1 2017 Number of Products under Investigation by Universities/Institutes, H1 2017 Products under Investigation by Universities/Institutes, H1 2017 Number of Products by Stage and Mechanism of Actions, H1 2017 Number of Products by Stage and Route of Administration, H1 2017 Number of Products by Stage and Molecule Type, H1 2017 Pipeline by Abion Inc, H1 2017 Pipeline by BioNTech AG, H1 2017 Pipeline by Cancer Research Technology Ltd, H1 2017 Pipeline by Etubics Corp, H1 2017 Pipeline by Genexine Inc, H1 2017 Pipeline by Hookipa Biotech AG, H1 2017 Pipeline by Inovio Pharmaceuticals Inc, H1 2017 Pipeline by MedImmune LLC, H1 2017 Pipeline by Rottapharm Biotech Srl, H1 2017 Pipeline by Selecta Biosciences Inc, H1 2017 Pipeline by Tomegavax Inc, H1 2017 Pipeline by Transgene SA, H1 2017 Dormant Projects, H1 2017 Discontinued Products, H1 2017
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
